Diagnostic accuracy of noninvasive steatosis biomarkers with magnetic resonance imaging proton density fat fraction as gold standard

Figure 4 Area under the receiver operating characteristic curves. A: The steatosis biomarkers for detecting nonalcoholic fatty liver disease [magnetic resonance imaging proton density fat fraction (MRI-PDFF) ≥ 5%]; B: The steatosis biomarkers for detecting moderate-to-severe steatosis (MRI-PDFF ≥ 11%); C: The steatosis biomarkers for detecting severe steatosis (MRI-PDFF ≥ 17%). AUC: Area under the receiver operating characteristic curve.